Article date 06/08/20Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
Mesenchymal stem cell (MSC)-based therapies haveattracted much attention because of their powerful selfrenewal capability and pluripotency [15,16]. Currently,MSCs have been widely used in cell therapy, including alarge number of basic research and clinical trials [17–19].Safety and effectiveness have been documented in manyclinical trials, especially those dealing with immunemediated inflammatory diseases, such as graft-versus-hostdisease and systemic lupus erythematosus [20,21]. One ofthe main functions of MSCs is immune regulation, whichcan alleviate the inflammatory response in the bodythrough immunosuppression [22–24]. MSCs possess theability to alleviate inflammatory response and can thusserve as a potential treatment for patients with COVID-19
https://pubmed.ncbi.nlm.nih.gov/32761491/ - Abstract
https://link.springer.com/content/pdf/10.1007/s11684-020-0810-9.pdf Full Article
Case 2A 71-year-old man living in Wuhan, China was diagnosedat Wuhan Seventh People’s Hospital on January 28, 2020.The patient presented with fever for 20 days, dyspnea,cough for 10 days, and a body temperature of 39 °C. Then,he presented with dyspnea and cough for 4 days and wasadmitted to the Renmin Hospital of Wuhan University onFebruary 7, 2020. Physical examination showed dyspneaand cough, a body temperature of 36.5 °C, breathing rate of34 times per minute, and pulse of 96 times per minute.SaO2 was 98%, and PO2 was 99 mmHg on the basis of80% FiO2. The laboratory tests showed a decreasedleukocyte count (2.6 109/L), increased neutrophils(81.3%), and decreased lymphocytes (10.5%) (Table 2).The inflammatory indicators showed elevated CRP (15.5mg/L) and normal IL-6 (5.1 pg/mL). The real-timefluorescence polymerase chain reaction of the patient’ssputum was positive for the SARS-CoV-2 nucleic acid.The chest X-ray indicated patchy and high-densityshadows in the lower lung fields and the left middle lung(Fig. 3).
During hospitalization, ribavirin, arbidol hydrochloride,cefoperazone-sulbactam, lowering of blood pressure, andother symptomatic supportive treatments were given to thepatient. At the same time, the patient received MSCtreatment via intravenous infusion three times on February8, 9, and 11, 2020. The injection dose of MSCs wasdetermined as 1 million per kg body weight [34]. Amultiple intravenous infusion of allogeneic MSCs was welltolerated in the patient with SARS-CoV-2-induced ARDS.SaO2 was 99%, and PO2 was 169 mmHg on the basis of30% oxygen concentration on February 15, 2020. The dynamic changes in the laboratory examination are shownin Table 2. We found that after the MSC treatment, thelymphocytes increased, the inflammation indicators, especially CRP, decreased, and FiO2 declined (Table 2). Repeatchest X-ray showed the absorption of high-density exudatein the lower lung fields and left middle lung (Fig. 3). Theexpression of SARS-CoV-2 was negative according to thetest of nucleic acid on February 16 and 19, 2020. A followup on the patient was conducted on February 22, 2020.
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
Article date 06/08/20Clinical study using mesenchymal stem cells...
- There are more pages in this discussion • 12,070 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
55.5¢ |
Change
0.060(12.1%) |
Mkt cap ! $633.0M |
Open | High | Low | Value | Volume |
50.0¢ | 59.0¢ | 48.5¢ | $16.88M | 30.80M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 99223 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.0¢ | 44000 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 99223 | 0.555 |
12 | 129157 | 0.550 |
5 | 107360 | 0.545 |
16 | 329826 | 0.540 |
2 | 67148 | 0.535 |
Price($) | Vol. | No. |
---|---|---|
0.560 | 44000 | 4 |
0.565 | 310 | 1 |
0.570 | 164673 | 5 |
0.575 | 43000 | 3 |
0.580 | 226348 | 7 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
55.5¢ |
  |
Change
0.060 ( 15.7 %) |
|||
Open | High | Low | Volume | ||
50.5¢ | 59.0¢ | 48.5¢ | 11524458 | ||
Last updated 16.02pm 28/03/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online